NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Regencell Bioscience Holdings Limited (RGC) Stock Analysis

Regencell Bioscience Holdings Limited (RGC) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

RGC

$6.89

+$0.41 (+6.33%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RGC with… →

RGC Key Statistics

As of Sep 4, 2026

Trading

Open: $6.43
Previous Close: $6.48
Day's Range: 6.35–7.65
52-Week Range: 4.51–69.00
Volume: 656.00K
Beta: 1.43

Valuation

P/E Ratio: unprofitable
EPS (ttm): −0.01

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$4.30M
Profit margin: 0.00%
1-Year Return: −46.34%

Dividend and dates

Earnings Date: October 28, 2026estimated
Avg Volume: 314.94K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RGC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+203.37%−12.44%−62.35%−52.95%+16053.85%−67.19%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−67.19%
2025	+16053.85%
2024	−52.95%
2023	−62.35%
2022	−12.44%
2021 (partial year)	+203.37%

As of September 4, 2026.

RGC Revenue and Earnings by Fiscal Year

FY ends June

RevenueNet income

202220232024

Fiscal year	Revenue	Net income	Net margin
2024	$0.00	−$4.30M	—
2023	$0.00	−$5.87M	—
2022	$0.00	−$7.45M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2024	$0.00	—	−$4.74M	−$4.30M	—
2023	$0.00	—	−$6.27M	−$5.87M	—
2022	$0.00	—	−$7.62M	−$7.45M	—

Annual figures as reported, in the company's reporting currency. As of June 30, 2024.

RGC Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks

Metric	RGC	Drug Manufacturers - Specialty & Generic median	vs median
Profit margin	0.00%	−3.14%	3.1 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Regencell Bioscience Holdings Limited trades under the ticker RGC. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 10.

The 52-week range on file runs from $4.51 to $69.00. RGC last closed at $6.89 on September 4, 2026. That is +$0.41 (+6.33%) against the previous close. The latest close sits 52.77% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2024, shows revenue of $0.00. The same year closed with a net loss of $4.30M. Profit margin runs at 0%. That is 3.1 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −0.01.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2024. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.43. Annualized volatility over the trailing 5 years is 277.57%. The trailing one-year price return is −46.34%. Measured over 5 years, that is +54.43% a year compounded.

Growth & Income

No dividend is on file for RGC.

So far in 2026 the price is −67.19%. The strongest complete calendar year on file is 2025 at +16,053.85%; the weakest is 2023 at −62.35%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Regencell Bioscience Holdings Limited (RGC) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Regencell Bioscience Holdings Limited	RGC	—	—
Takeda Pharmaceutical Company Limited	TAK	$58.92B	—
Teva Pharmaceutical Industries Limited	TEVA	$42.37B	60.6
Haleon plc	HLN	$42.22B	20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Regencell Bioscience Holdings Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

TEVA

Teva Pharmaceutical Industries Limited

$42.37B

HLN

Haleon plc

$42.22B

ZTS

Zoetis Inc.

$31.33B

UTHR

United Therapeutics Corporation

$20.91B

VTRS

Viatris Inc.

$19.39B

View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Visit website →